Study of CREXONT for Parkinson's with wearing-off episodes
Part of Brain & nervous system clinical trials.
This study tests how well CREXONT, an extended-release form of carbidopa-levodopa, controls symptoms in people with Parkinson's who experience predictable 'off' periods when their regular medication wears off. The goal is to see if it can reduce the daily hours of poor mobility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Parkinson's disease and currently take carbidopa-levodopa tablets regularly.
- You have predictable 'off' times each day when your medication stops working well, totaling at least 2.5 hours awake.
- You must be able to tell when you are 'on' (medication working) versus 'off' (symptoms return), confirmed by a training session.
- You should not have had brain surgery for Parkinson's (like deep brain stimulation) or plan to have it during the study.
- You are willing to fill out daily diaries and attend all study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.
This trial tests an experimental drug called AP-472, taken alongside your regular Parkinson's medications, to see if it can reduce the amount of "OFF" time you experience each day when symptoms return between doses of levodopa.
This early-stage trial tests a new medication called Lu AF28996 in Chinese patients with Parkinson's disease who experience predictable on-off episodes (times when medication works well versus poorly). The study aims to see if this drug can help reduce those difficult off periods.
This study tests a new nasal spray called XJN010 for people with Parkinson's who have 'off' episodes—times when their regular medication wears off and symptoms come back. The goal is to see if the spray can safely and effectively help during those periods.
This study is looking at how a new continuous 24-hour injection treatment (foslevodopa/foscarbidopa) affects quality of life in people with advanced Parkinson's disease. It is a real-world study, meaning you just take the medication as your doctor prescribes, and researchers observe the results.
This study checks whether measuring levodopa (a Parkinson medicine) in real time can help better understand Parkinson medication effects. You may be asked to wear/perform study monitoring while taking your usual carbidopa/levodopa tablets.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.